872509-56-3

Basic information

• Product Name: 2,6-Dichloro-3,5-dimethoxyaniline
• Synonyms: 2,6-Dichloro-3,5-dimethoxyaniline;2,6-Dichloro-3,5-dimethoxybenzenamine;Benzenamine, 2,6-dichloro-3,5-dimethoxy-;2,6-Dichloro-3,5-dimethoxy-phenylamine
• CAS NO: 872509-56-3
• Molecular Formula: C₈H₉Cl₂NO₂
• Molecular Weight: 222.06856
• Mol File: 872509-56-3.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 320℃
• Flash Point: 147℃
• Appearance: /
• Density: 1.357
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: -0.13±0.10(Predicted)
• CAS DataBase Reference: 2,6-Dichloro-3,5-dimethoxyaniline(CAS DataBase Reference)
• NIST Chemistry Reference: 2,6-Dichloro-3,5-dimethoxyaniline(872509-56-3)
• EPA Substance Registry System: 2,6-Dichloro-3,5-dimethoxyaniline(872509-56-3)

Safety Data

• Hazardous Substances Data: 872509-56-3(Hazardous Substances Data)

Usage

Uses

Used in Dye and Pigment Production:
2,6-Dichloro-3,5-dimethoxyaniline is used as a chemical intermediate for the production of dyes and pigments. Its unique chemical structure allows for the creation of a wide range of colorants used in various industries.
Used in Pharmaceutical Synthesis:
In the pharmaceutical industry, 2,6-Dichloro-3,5-dimethoxyaniline serves as a key intermediate in the synthesis of certain drugs. Its reactivity and functional groups make it a valuable component in the development of new medicinal compounds.
Used in Agricultural Chemicals:
2,6-Dichloro-3,5-dimethoxyaniline is also utilized as an intermediate in the production of agricultural chemicals. Its role in the synthesis of various agrochemicals contributes to its importance in this sector.
Safety Precautions:
Given its moderately toxic nature, 2,6-Dichloro-3,5-dimethoxyaniline requires careful handling to prevent irritation and potential harm to individuals and the environment. Proper safety measures, including the use of personal protective equipment and adherence to safety protocols, are essential when working with this chemical compound.

Upstream product

• 75177-59-2 2,6-dichloro-3,5-dimethoxybenzoic acid 
• 1132-21-4 3,5-dimethoxybenzoic acid 
• 10272-07-8 3.5-dimethoxyaniline 
• 79257-61-7 N-(3,5-dimethoxy-phenyl)-acetamide 
• 943189-21-7 N-(2,6-dichloro-3,5-dimethoxy-phenyl)-acetamide 

Relevant articles and documents

Heterocyclic compounds as FGFR4 inhibitors

The present invention provides heterocyclic compounds as selective inhibitors of fibroblast growth factor receptor 4 (FGFR4), pharmaceutical compositions containing the compounds, methods of preparingthe compounds, and methods of treating cell proliferative diseases, such as cancer, using the compounds of the invention.

Pyrido[2,3-b]pyrazine-3(4H)-ketone derivative and application thereof

The invention provides a pyrido[2,3-b]pyrazine-3(4H)-ketone derivative and application thereof. The structural general formula of the pyrido[2,3-b]pyrazine-3(4H)-ketone derivative is a formula V, andthe pyrido[2,3-b]pyrazine-3(4H)-ketone derivative comprises pharmaceutically acceptable salt, solvate, hydrate or crystal form thereof. The compound provided by the invention is an active ligand of afibroblast growth factor receptor (FGFR), and research shows that the compound shown in the structure V has good anti-proliferative activity on KATO III gastric cancer cells (FGFR2 amplification) andHuh-7 liver cancer cells (FGFR4 overexpression), and is applied to preparation of drugs for treating tumor-related diseases caused by FGFR abnormal activation as an FGFR inhibitor. The structural general formula V is shown in the description.

Preparation method of kinase inhibitor intermediate

The invention relates to a synthetic method of a kinase inhibitor intermediate, namely 2, 6-dichloro-3, 5-methoxyaniline (I), belongs to the field of organic synthesis, and has the advantages of safeand stable route, convenience in operation, easiness in

HETEROARYLAMINE DERIVATIVES AS PROTEIN KINASE INHIBITORS

A heteroarylamine compound includes protein kinase inhibition activity, a pharmaceutically acceptable salt thereof and a pharmaceutical composition for preventing and treating a disease caused by abnormal cell growth, which contains the compound as an act

FGFR4 INHIBITORS

Methods, compounds, pharmaceutical compositions, and methods of preparing medicaments for treating hepatocellular carcinoma having an altered FGFR4 and/or FGF19 status.

FGFR4 INHIBITORS

We provide FGFR inhibitors, their salts, methods of manufacture, and methods of use.

BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS

The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR4 enzyme and are useful in the treatment of FGFR4-associated diseases such as cancer.

PYRIMIDINE FGFR4 INHIBITORS

Provided herein are compounds of Formula I useful as FGFR4 inhibitors, as well as methods of use of the same.

Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl- piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase

A novel series of N-aryl-N′-pyrimidin-4-yl ureas has been optimized to afford potent and selective inhibitors of the fibroblast growth factor receptor tyrosine kinases 1, 2, and 3 by rationally designing the substitution pattern of the aryl ring. On the b

[4,5']BIPYRIMIDINYL-6,4'-DIAMINE DERIVATIVES AS PROTEIN KINASE INHBITORS

The invention provides a novel class of compounds of the Formula (I): in which the symbols have the meanings given in the description and claims, to pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prev